High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 47, Issue 7, 2006, Pages 1290-1294

  Hosing, Chitra ^a   Saliba, Rima M ^a   Körbling, Martin ^a   Acholonu, Sandra ^a   Mcmannis, John ^a   Anderlini, Paolo ^a   Giralt, Sergio ^a   De Lima, Marcos ^a   Okoroji, Grace Julia ^a   Couriel, Daniel R ^a   Champlin, Richard ^a   Khouri, Issa F ^a   Donato, Michele L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Lymphoma; Rituximab; Stem cell mobilization

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LIVER ENZYME; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE SULFATE;

ADULT; AGED; APHERESIS; ARTICLE; B CELL LYMPHOMA; BACTERIAL INFECTION; BODY WEIGHT; CANCER GRADING; CANDIDIASIS; CD34 SELECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER INJURY; MALE; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECIPIENT; STEM CELL MOBILIZATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; ETOPOSIDE; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IFOSFAMIDE; IMMUNOLOGIC FACTORS; KINETICS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 33747680934     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500468584     Document Type: Article

References (28)

1. Philip, T and Guglielmi, C and Hagenbeek, A and Somers, R and Van der Lelie, H and Bron, D and (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med, 333, pp. 1540-1545.
2. Vose, J and Sharp, G and Chan, W and Nichols, C and Loh, K and Inwards, D and (2002) Autologous transplantation for aggressive non-Hodgkin's lymphoma: Results of a randomized trial evaluating graft source and minimal residual disease J Clin Oncol, 20, pp. 2344-2352.
3. Sharp, J and Kessinger, A and Mann, S and Crouse, D and Armitage, J and Bierman, P and (1996) Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest J Clin Oncol, 14, pp. 214-219.
4. Coiffier, B and Lepage, E and Beiére, J and Herbrecht, R and Tilly, H and Bouabdallah, R and (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma N Engl J Med, 346, pp. 235-242.
5. Pfreundschuh, M and Trümper, L and Ma, D and Österborg, A and Pettengell, R and Trneny, M and (2004) Randomized Intergroup Trial of First Line Treatment for Patients ≤60 years with Diffuse Large B-cell non-Hodgkin's Lymphoma (DLBCL) with a CHOP-Like Regimen with or without the anti-CD20 Antibody Rituximab-Early Stopping after the First Interim Analysis Proc Am Soc Oncol, 22(556). (abstract #6500)
6. Kewalramani, T and Zelenetz, A and Nimer, S and Portlock, C and Straus, D and Noy, A and (2004) Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Blood, 103, pp. 3684-3688.
7. Horwitz, S and Negrin, R and Blume, K and Breslin, S and Stuart, M and Stockerl-Goldstein, K and (2004) Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma Blood, 103, pp. 777-783.
8. Khouri, I and Saliba, R and Hosing, C and Okoroji, G and Acholonu, S and Anderlini, P and (2005) Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas J Clin Oncol, 23, pp. 2240-2247.
9. Gianni, A and Magni, M and Martelli, M and Di Nicola, M and Carlo-Stella, C and Pilotti, S and (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) Blood, 102, pp. 749-755.
10. Flohr, T and Hess, G and Kolbe, K and Gamm, H and Nolte, H and Stanislawski, T and (2002) Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL Bone Marrow Transplant, 29, pp. 769-775.
11. Lazzarino, M and Arcaini, L and Bernasconi, P and Alessandrino, E and Gargantini, L and Cairoli, R and (2002) A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma Br J Haematol, 116, pp. 229-235.
12. Voso, M and Pantel, G and Weis, M and Schmidt, P and Martin, S and Moos, M and (2000) In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma Br J Haematol, 109, pp. 729-735.
13. Tothova, E and Kafkova, A and Guman, T and Stecova, N and Fricova, M. (2003) Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas Neoplasma, 50, pp. 22-25.
14. Belhadj, K and Delfau-Larue, M and Elgnaoui, T and Beaujean, F and Beaumont, J and Pautas, C and (2004) Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: A single institution study Ann Oncol, 15, pp. 504-510.
15. Buckstein, R and Imrie, K and Spaner, D and Potichnyj, A and Robinson, J and Nanji, S and (1999) Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma Semin Oncol, 26(5 Suppl 14), pp. 115-122.
16. Hoerr, A and Gao, F and Hidalgo, J and Tiwari, D and Blum, K and Mathews, V and (2004) Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma J Clin Oncol, 22, pp. 4561-4566.
17. Endo, T and Sato, N and Mogi, Y and Koizumi, K and Nishio, M and Fujimoto, K and (2004) Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma Bone Marrow Transplant, 33, pp. 703-707.
18. Arcaini, L and Orlandi, E and Alessandrino, E and Iacona, I and Brusamolino, E and Bonfichi, M and (2004) A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma Bone Marrow Transplant, 34, pp. 175-179.
19. Donato, M and Champlin, R and Van Besien, K and Körbling, M and Cabanillas, F and Anderlini, P and (1999) Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma Leukemia and Lymphoma, 35, pp. 317-324.
20. StataCorp. Stata Statistical Software: Release 7.0.(2001) College Station. Stata Corporation.
21. Trotti, A and Colevas, A and Setser, A and Rusch, V and Jaques, D and Budach, V and (2003) CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol, 13, pp. 176-181.
22. Benekli, M and Hahn, T and Shafi, F and Qureshi, A and Alam, A and Czuczman, M and (2003) Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients Bone Marrow Transplant, 32, pp. 139-143.
23. Lemieux, B and Tartas, S and Traulle, C and Espinouse, D and Thieblemont, C and Bouafia, F and (2004) Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma Bone Marrow Transplant, 33, pp. 921-923.
24. Flinn, I and O'Donnell, P and Goodrich, A and Vogelsang, G and Abrams, R and Noga, S and (2000) Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma Biol Blood Marrow Transplant, 6, pp. 628-632.
25. Hess, G and Flohr, T and Derigs, H. (2002) Rituximab as in vivo purging agent in autologous stem cell transplantation for relapsed B-NHL Ann Hematol, 81(Suppl 2), pp. S54-S55.
26. Magni, M and Di Nicola, M and Devizzi, L and Matteucci, P and Lombardi, F and Gandola, L and (2000) Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion Blood, 96, pp. 864-869.
27. Friedman, J and Lazarus, H and Koc, O. (2000) Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation Bone Marrow Transplant, 26, pp. 831-836.
28. Gribben, J and Neuberg, D and Freedman, A and Gimmi, C and Pesek, K and Barber, M and (1993) Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma Blood, 81, pp. 3449-3457.